Meeting
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
Presenter
Jing Pan, PhD
State Key Laboratory of Experimental Hematology, Department of Hematology, Beijing Boren Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT05032599
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7028)
DOI
10.1200/JCO.2022.40.16_suppl.7028
Abstract #
7028
Poster Bd #
259
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.
Speaker: Biao Zheng, MD, PhD
Videos & Slides
2020 ASCO Virtual Scientific Program
GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.
Speaker: Adam D. Cohen, MD
Videos & Slides
2016 ASCO Annual Meeting
Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.
Speaker: David L. Porter, MD
Videos & Slides
2015 ASCO Annual Meeting
Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas.
Speaker: Stephen J. Schuster, MD